ImmunoGen
As of the edition of 20 October 2026, ImmunoGen runs 8 drugs, 1 of them marketed; it is on route A at 5 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
ImmunoGen was acquired in 2024; successor ABBVIE.
- ImmunoGen, Inc.: acquired in 2024; successor ABBVIE
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 4 |
| Stopped | 2 |
| Status not established | 1 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Mirvetuximab soravtansine | Ends 2034 (computed from the first US licence) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 5 targets, route B at 1 target.
All 6 rows on route A or B
In the product6 company-target rows on route A or B; 3 are not shown here, and no score is.
See all 6 targets where ImmunoGen needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 14 trials led
- Hormones: 5 trials led
- Blood and lymph: 4 trials led